RT Journal Article
T1 Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis
A1 Órpez-Zafra, Teresa
A1 Pavía-Molina, José
A1 Pinto-Medel, Maria Jesús
A1 Hurtado-Guerrero, Isaac
A1 Rodríguez-Bada, José Luis
A1 Martín-Montañez, Elisa
A1 Fernández Fernández, Óscar
A1 Leyva-Fernández, Laura
A1 Oliver-Martos, Begoña
K1 Esclerosis múltiple
AB Aim: The soluble isoform of the IFN-β receptor (sIFNAR2) can bind IFN-β and modulate its activity, although its role in autoimmune diseases remains unknown.Methods: A recombinant human sIFNAR2 protein was cloned, expressed and purified after which we developed and validated an ELISA for its quantification in human serum. Serum sIFNAR2 were assessed in multiple sclerosis (MS) patients and healthy controls.Results: The ELISA has a dynamic range of 3.9-250 ng/ml and a detection limit of 2.44 ng/ml. Serum sIFNAR2 were significantly lower in untreated-MS patients than in healthy controls.Conclusion: The ELISA is suitable for quantification of sIFNAR2 in serum and should facilitate the study of sIFNAR2 in neuroimmunological diseases such as MS.
PB Taylor & Francis
YR 2015
FD 2015
LK https://hdl.handle.net/10630/33935
UL https://hdl.handle.net/10630/33935
LA eng
NO Órpez-Zafra T, Pavía J, Pinto-Medel MJ, Hurtado-Guerrero I, Rodriguez-Bada JL, Martín Montañez E, Fernández Ó, Leyva L, Oliver-Martos B. Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis. Bioanalysis. 2015;7(22):2869-80. doi: 10.4155/bio.15.208. Epub 2015 Nov 16. PMID: 26571364.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026